Autopsy report · NCT02718482

Phase II Trial for the Treatment of Relapsed Osteosarcoma

“Not adequate enrollment (sample size not possible to reach)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 9 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Italian Sarcoma Group

Sponsor type

University, hospital or other

Conditions

OSTEOSARCOMA

Interventions

Gemcitabine and Docetaxel; Ifosfamide

Participants

7

Sites

10

Countries

Italy

Trials that died the same way

• Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients
  “Target sample size not reached for enrollment.” (80% match in meaning)
• Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants
  “Not sufficient enrollment” (80% match in meaning)
• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (80% match in meaning)
• Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.
  “insufficient enrollment” (79% match in meaning)
• Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
  “Insufficient enrollment rate” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.